Shots:
Arthrosi Therapeutics has completed patient enrolment in P-III (REDUCE 1) trial of pozdeutinurad (AR882) to reduce the serum urate (sUA) levels & tophi in gout and tophaceous gout pts
The P-III (REDUCE 1) trial assessed pozdeutinurad (50 or 75mg) vs PBO in 750 pts with a majority being inadequate responders to urate lowering therapies…
